Background: Although several polymorphisms in olanzapine-metabolizing enzymes have
been identified, the clear role and benefit for pharmacotherapy remain uncertain. The aim of …

Psychiatric pharmacotherapy with olanzapine is commonplace. We investigated the
influence of CYP1A2* 1F (− 163A, rs762551) and serotonergic polymorphisms on …

Objective Metabolism of the atypical antipsychotic olanzapine (OLA) is partially catalyzed by
cytochrome P450 (CYP) 1A2, a target of aryl hydrocarbon receptor (AHR)-mediated …

Background: The relationship between a daily dose of olanzapine, its serum concentration,
and the genotype of young nonsmoking men treated for schizophrenia or schizophreniform …

The pharmacokinetics of the atypical antipsychotic, olanzapine, display large interindividual
variation leading to multiple-fold differences in drug exposure between patients at a given …

Objective: Limited data suggest that CYP1A2 and CYP2D6 are involved in the metabolism of
olanzapine. The purpose of this study was to further elucidate the role of these enzymes in …

Olanzapine is a commonly prescribed atypical antipsychotic agent for treatment of patients
with schizophrenia and bipolar disorders. Previous in vitro studies using human liver …

Olanzapine is an atypical antipsychotic widely used for the treatment of schizophrenia,
which often causes serious adverse drug reactions. Currently, there are no clinical …

Objective The pharmacokinetics of olanzapine and response to treatment could be affected
by polymorphisms in genes coding for drug‐metabolizing enzymes, transporters, or …

This study investigated whether the smokinginducible cytochrome P450 (CYP) 1A2 and the
polymorphic CYP2D6 play significant roles in the metabolism of olanzapine and its clinical …